89976-27-2

Usage

Uses

Methyl 4-iodo-3-nitrobenzoate is used as pharmaceutical intermediate.

InChI:InChI=1/C8H6INO4/c1-14-8(11)5-2-3-6(9)7(4-5)10(12)13/h2-4H,1H3

Upstream product

• 67-56-1 methanol 
• 35674-27-2 4-iodo-3-nitrobenzoic acid 
• 619-58-9 4-iodobenzoic acid 
• 74-88-4 methyl iodide 
• 1445-45-0 Trimethyl orthoacetate 
• 1588-83-6 4-amino-3-nitrobenzoic acid 
• 619-44-3 methyl 4-iodobenzoate 

Downstream Products

• 98341-63-0 4-(5,6-dimethoxy-3-oxo-phthalan-4-yloxy)-3-nitro-benzoic acid methyl ester 
• 32117-05-8 methyl 3-nitro-4-(piperidin-1-yl)benzoate 
• 412947-54-7 methyl 3-amino-4-iodobenzoate 
• 1135859-04-9 C₂₀H₂₅N₃O₆ 
• 1321627-86-4 methyl 3-nitro-4-(phenylethynyl)benzoate 
• 1344728-39-7 C₁₃H₁₃NO₆ 
• 1344728-21-7 C₁₃H₁₃NO₅ 
• 1344728-31-9 C₁₄H₁₅NO₅ 
• 1227244-11-2 3-amino-4-[N-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)amino]benzoic acid methyl ester 
• 1227244-12-3 3-amino-4-[N-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)amino]benzoic acid methyl ester 
• 1227244-15-6 C₂₄H₃₀N₂O₃ 
• 1227244-16-7 C₂₅H₃₂N₂O₃ 
• 259219-18-6 3-nitro-4-[N-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)amino]benzoic acid methyl ester 
• 1227244-08-7 3-nitro-4-[N-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)amino]benzoic acid methyl ester 

Relevant academic research and scientific papers

Modulating Guest Uptake in Core–Shell MOFs with Visible Light

A two-component core–shell UiO-68 type metal–organic framework (MOF) with a nonfunctionalized interior for efficient guest uptake and storage and a thin light-responsive outer shell was prepared by initial solvothermal MOF synthesis followed by solvent-as

Thermal decomposition pathways of nitro-functionalized metal-organic frameworks

The decomposition behavior of high energy metal-organic frameworks (MOFs) with extensive nitration is disclosed. In contrast to the detonation behavior observed in molecular energetic compounds, deflagration transforms cubic MOFs into anisotropic carbon s

HEPATITIS B CORE PROTEIN MODULATORS

The present disclosure provides, in part, compounds having allosteric effector properties against Hepatitis B virus Cp. Also provided herein are methods of treating viral infections, such as hepatitis B, comprising administering to a patient in need thereof a disclosed compound.

SUBSTITUTED BICYCLIC HETEROARYL COMPOUNDS AS RXR AGONISTS

The present invention relates to certain substituted bicyclic compounds that are agonists of RXR and which are therefore useful in the treatment of certain disorders that can be prevented or treated by activation of this receptor. In addition the invention relates to the compounds, methods for their preparation, pharmaceutical compositions containing the compounds and the uses of these compounds in the treatment of certain disorders.

A significant enhancement of water vapour uptake at low pressure by amine-functionalization of UiO-67

The functionalization of UiO-67 with -NH2 groups enhances CO2 and CH4 adsorption at 1 bar and 298 K and positively influences the framework's interaction with water as evidenced by the significant enhancement of water vapo

Mechanism of retinoid X receptor partial agonistic action of 1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)-1H-benzotriazole-5- carboxylic acid and structural development to increase potency

We have reported that retinoid X receptor (RXR) partial agonist 1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)-1H-benzotriazole-5- carboxylic acid (CBt-PMN, 4a) shows a significant antidiabetes effect in the KK-Ay type 2 diabetes model

PROCESS FOR THE PREPARATION OF 4-IODO-3-NITROBENZAMIDE

A process for the preparation of 4-iodo-3-nitrobenzamide free from the impurities formed due to nucleophilic substitution of the labile iodo group is disclosed.

BENZAMIDE DERIVATIVE WITH ANTICANCER ACTIVITY AND PREPARATION METHOD AND USE THEREOF

Provided are a benzamide derivative as shown in formula (I) or a pharmaceutically acceptable salt thereof, and the preparation method and use thereof for preparing a medicine for treating cancer, wherein the group definitions of formula (I) are as set out

RXR partial agonist CBt-PMN exerts therapeutic effects on type 2 diabetes without the side effects of RXR full agonists

Treating insulin resistance and type 2 diabetes in rodents, currently known retinoid X receptor (RXR) agonists induce significant adverse effects. Here we introduce a novel RXR partial agonist CBt-PMN (11b), which shows a potent glucose-lowering effect and improvements of insulin secretion and glucose tolerance without the serious adverse effects caused by RXR full agonists. We suggest that RXR partial agonists may be a new class of antitype 2 diabetes drug candidates.

NOVEL MCH RECEPTOR ANTAGONISTS

The present invention relates to a melanin concentrating hormone antagonist compound of formula I: or a pharmaceutically acceptable salt thereof, useful for the treamtment useful fog treating Type H diabetes and/or obesity.